Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
NCT01824615
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Adverse Effects
Interventions
DRUG:
Sunitinib
Sponsor
Cathay General Hospital